| Literature DB >> 34421499 |
Mara Dierssen1,2,3, Yann Herault4, Pablo Helguera5, Maria Martínez de Lagran1,3, Anna Vazquez2, Bradley Christian6, Maria Carmona-Iragui7,8, Frances Wiseman9, William Mobley10, Elizabeth M C Fisher11, Veronique Brault4, Anna Esbensen12, Lisa M Jacola13, Marie Claude Potier14, Eric D Hamlett15, Leonard Abbeduto16, Laura Del Hoyo Soriano16, Jorge Busciglio17, Maria Florencia Iulita18, John Crispino19, Sébastien Malinge20, Eugenio Barone21, Marzia Perluigi21, Floriana Costanzo22, Jean Maurice Delabar14, Renata Bartesaghi23, Alain D Dekker24, Peter De Deyn24,25, Juan Fortea Ormaechea7,8, Patricia A Shaw26, Tarik F Haydar26, Stephanie L Sherman27, André Strydom28, Anita Bhattacharyya6.
Abstract
Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.Entities:
Keywords: Alzheimer's disease; Biomarkers; Down syndrome; Intellectual disability; Language impairment; Mouse models; Neurodevelopmental disorders; Trisomy 21 Research Society
Year: 2021 PMID: 34421499 PMCID: PMC8339505 DOI: 10.1159/000514437
Source DB: PubMed Journal: Mol Syndromol ISSN: 1661-8769